Thursday, 8 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

GPT Healthcare Earnings Call: Key Takeaways

GPT Healthcare reported Q4 FY26 revenue of ₹128cr (+24% YoY) and EBITDA margin of 19.5%. FY26 revenue stood at ₹478.5cr with an 18.8% margin.

Highlights
Revenue growthFY26 revenue ₹478.5cr. Guided 15% growth for FY27.
MarginsTargeting 20.2% EBITDA margin; 100bps improvement expected for FY27.
Demand visibilityHigh demand for tertiary care; Raipur ramping up to 30% occupancy.
Management confidenceStrong outlook on Eastern India; Raipur hospital expected to breakeven Q3.

Growth

FY26 revenue up to ₹478.5cr; EBITDA ₹90.1cr. Mature hospitals EBITDA margin improved to 23.06%.

Outlook

FY27 revenue guidance of 15% growth; 150-bed Jamshedpur hospital to commission in Q4 FY27.

Risks

Negative EBITDA of ₹13.8cr at Raipur; regional competition and medical staff attrition risk.

Source

Earnings Call filed with BSE, NSE: GPTHEALTH. Summary written with AI assistance from the document.

Read the document ↗

GPT Healthcare Ltd: key numbers

Share price
₹146.34
Market cap
₹1,201 Cr
Revenue (annual)
₹472.6 Cr
Net profit (annual)
₹42.22 Cr
P/E (TTM)
25.4×Sector 53.1×
Promoter holding
65.57%+0.00% QoQ
FII holding
3.03%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from GPT Healthcare Ltd

All →
20:31 IST BSE
Annual General Meeting

GPT Healthcare Annual General Meeting

GPT Healthcare Limited held its 37th Annual General Meeting on August 6, 2026. Shareholders transacted ordinary and special business items as stated in the notice.

17:25 IST BSE
Results Update

GPT Healthcare Results Update

GPT Healthcare reported Q1 FY27 financial results. Total income grew 18% year-over-year to ₹128.2 Crore, reflecting steady operational performance.

13:36 IST BSE
Board Meeting Date

GPT Healthcare Board Meeting Date

GPT Healthcare Limited has scheduled a board meeting for August 3, 2026, to consider and approve the company's unaudited financial results for the first quarter.